Jund and junb integrate prostaglandin e2 activation of breast cancer-associated proximal aromatase promoters

Molecular Endocrinology

Volumn 25, Issue 5, 2011, Pages 767-775

  Chen, Dong ^a   Reierstad, Scott ^c,d   Fang, Feng ^b   Bulun, Serdar E ^a  

^a Division of Reproductive Biology Research   (United States)

^b Department of Obstetrics and Gynecology   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d APPLIED BIOSYSTEMS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; AROMATASE; CRE RECOMBINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 14; PROSTAGLANDIN E2; PROTEIN C JUN; PROTEIN KINASE C; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR JUND;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADIPOSE TISSUE; AROMATASE; BASE SEQUENCE; BREAST NEOPLASMS; DINOPROSTONE; FEMALE; FIBROBLASTS; GENE COMPONENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; LUCIFERASES, RENILLA; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-JUN; REGULATORY ELEMENTS, TRANSCRIPTIONAL; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION;

EID: 79955764238     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2010-0368     Document Type: Article

References (39)

1. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, Gurates B, Tamura M, Langoi D, Deb S 2005 Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 57:359-383
2. Chen D, Reierstad S, Lu M, Lin Z, Ishikawa H, Bulun SE 2009 Regulation of breast cancer-associated aromatase promoters. Can-cer Lett 273:15-27
3. Kamat A, Hinshelwood MM, Murry BA, Mendelson CR 2002 Mechanisms in tissue-specific regulation of estrogen biosynthesis in humans. Trends Endocrinol Metab 13:122-128
4. Mahendroo MS, Mendelson CR, Simpson ER 1993 Tissue-specific and hormonally controlled alternative promoters regulate aroma- tase cytochrome P450 gene expression in human adipose tissue. J Biol Chem 268:19463-19470
5. Jordan VC, Brodie AM 2007 Development and evolution of ther-apies targeted to the estrogen receptor for the treatment and pre- vention of breast cancer. Steroids 72:7-25
6. Yue W, Wang JP, Li Y, Bocchinfuso WP, Korach KS, Devanesan PD, Rogan E, Cavalieri E, Santen RJ 2005 Tamoxifen versus aro-matase inhibitors for breast cancer prevention. Clin Cancer Res 11:925s-930s
7. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T 2002 Anastrozole alone or in combination with tamox- ifen versus tamoxifen alone for adjuvant treatment of postmeno-pausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131-2139
8. Morales L, Neven P, Paridaens R 2005 Choosing between an aro-matase inhibitor and tamoxifen in the adjuvant setting. Curr Opin Oncol 17:559-565
9. Purohit A, Ghilchik MW, Duncan L, Wang DY, Singh A, Walker MM, Reed MJ 1995 Aromatase activity and interleukin-6 produc- tion by normal and malignant breast tissues. J Clin Endocrinol Metab 80:3052-3058
10. Schrey MP, Patel KV 1995 Prostaglandin E2 production and me-tabolism in human breast cancer cells and breast fibroblasts. Reg-ulation by inflammatory mediators. Br J Cancer 72:1412-1419
11. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER 1997 Tran-scriptional regulation of CYP19 gene (aromatase) expression in adipose stromal cells in primary culture. J Steroid Biochem Mol Biol 61:203-210
12. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER 1996 Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137:5739-5742
13. Chen D, Reierstad S, Lin Z, Lu M, Brooks C, Li N, Innes J, Bulun SE 2007 Prostaglandin E2 induces breast cancer related aromatase promoters via activation of p38 and c-Jun NH2-terminal kinase in adipose fibroblasts. Cancer Res 67:8914-8922
14. Bogoyevitch MA, Kobe B 2006 Uses for JNK: the many and varied infstrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev 70:1061-1095
15. Lallemand D, Spyrou G, Yaniv M, Pfarr CM 1997 Variations in Jun and Fos protein expression and AP-1 activity in cycling, resting and stimulated fibroblasts. Oncogene 14:819-830
16. Yazgan O, Pfarr CM 2002 Regulation of two JunD isoforms by Jun N-terminal kinases. J Biol Chem 277:29710-29718
17. Morton S, Davis RJ, Cohen P 2004 Signalling pathways involved in multisite phosphorylation of the transcription factor ATF-2. FEBS Lett 572:177-183
18. Mechta-Grigoriou F, Gerald D, Yaniv M 2001 The mammalian Jun proteins: redundancy and specificity. Oncogene 20:2378-2389
19. Nakabeppu Y, Ryder K, Nathans D 1988 DNA binding activities of three murine Jun proteins: stimulation by Fos. Cell 55:907-915
20. Fitzpatrick SL, Richards JS 1993 Cis-acting elements of the rat aro-matase promoter required for cyclic adenosine 3,5 -monophos- phate induction in ovarian granulosa cells and constitutive expres- sion in R2C Leydig cells. Mol Endocrinol 7:341-354
21. Clyne CD, Speed CJ, Zhou J, Simpson ER 2002 Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in prea- dipocytes. J Biol Chem 277:20591-20597
22. Ghosh S, Wu Y, Li R, Hu Y 2005 Jun proteins modulate the ovary-specific promoter of aromatase gene in ovarian granulosa cells via a cAMP-responsive element. Oncogene 24:2236-2246
23. McInnes KJ, Brown KA, Knower KC, Chand AL, Clyne CD, Simp-son ER 2008 Characterisation of aromatase expression in the hu-man adipocyte cell line SGBS. Breast Cancer Res Treat 112:429-435
24. Díaz-Cruz ES, Shapiro CL, Brueggemeier RW 2005 Cyclooxygen-ase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 90:2563-2570
25. Agarwal VR, Bulun SE, Leitch M, Rohrich R, Simpson ER 1996 Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab 81:3843-3849
26. Utsumi T, Harada N, Maruta M, Takagi Y 1996 Presence of alter-natively spliced transcripts of aromatase gene in human breast can- cer. J Clin Endocrinol Metab 81:2344-2349
27. Zhou C, Zhou D, Esteban J, Murai J, Siiteri PK, Wilczynski S, Chen S 1996 Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction. J Steroid Biochem Mol Biol 59:163-171
28. Girault I, Lerebours F, Tozlu S, Spyratos F, Tubiana-Hulin M, Lidereau R, Bieche I 2002 Real-time reverse transcription PCR assay of CYP19 expression: application to a well-defined series of post-menopausal breast carcinomas. J Steroid Biochem Mol Biol 82:323-332
29. Harada N 1997 Aberrant expression of aromatase in breast cancer tissues. J Steroid Biochem Mol Biol 61:175-184
30. Irahara N, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S 2006 Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-, IL-6 and COX-2 mRNAs in human breast cancer. Int J Cancer 118:1915-1921
31. Chiu R, Angel P, Karin M 1989 Jun-B differs in its biological prop-erties from, and is a negative regulator of, c-Jun. Cell 59:979-986
32. Brown KA, McInnes KJ, Hunger NI, Oakhill JS, Steinberg GR, Simpson ER 2009 Infcellular localization of cyclic AMP-respon-sive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmeno-pausal women. Cancer Res 69:5392-5399
33. Sofi M, Young MJ, Papamakarios T, Simpson ER, Clyne CD 2003 Role of CRE-binding protein (CREB) in aromatase expression in breast adipose. Breast Cancer Res Treat 79:399-407
34. Thépot D, Weitzman JB, Barra J, Segretain D, Stinnakre MG, Babi-net C, Yaniv M 2000 Targeted disruption of the murine junD gene results in multiple defects in male reproductive function. Develop- ment 127:143-153
35. Deb S, Zhou J, Jianfeng Z, Amin SA, Imir AG, Gonca IA, Yilmaz MB, Bertan YM, Lin Z, Zihong L, Bulun SE 2006 A novel role of sodium butyrate in the regulation of cancer-associated aromatase promoters I.3 and II by disrupting a transcriptional complex in breast adipose fibroblasts. J Biol Chem 281:2585-2597
36. Chen D, Fucini RV, Olson AL, Hemmings BA, Pessin JE 1999 Osmotic shock inhibits insulin signaling by maintaining Akt/pro- tein kinase B in an inactive dephosphorylated state. Mol Cell Biol 19:4684-4694
37. Daitoku H, Yamagata K, Matsuzaki H, Hatta M, Fukamizu A 2003 Regulation of PGC-1 promoter activity by protein kinase B and the forkhead transcription factor FKHR. Diabetes 52:642-649
38. Ohtake F, Takeyama K, Matsumoto T, Kitagawa H, Yamamoto Y, Nohara K, Tohyama C, Krust A, Mimura J, Chambon P, Yanag- isawa J, Fujii-Kuriyama Y, Kato S 2003 Modulation of oestrogen receptor signalling by association with the activated dioxin recep-tor. Nature 423:545-550
39. Zhou J, Gurates B, Yang S, Sebastian S, Bulun SE 2001 Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein. Cancer Res 61:2328-2334